In order for markets to grow and come up with new and improved products, research and development (R&D) and clinical trials play a crucial role. When companies invest in extensive research, they can create better and more effective products that help treat patients, ultimately contributing to the growth of the market. There are many products currently being tested and going through clinical trials, and if these get the green light from the proper regulatory authorities, they have the potential to greatly boost market growth.
As of now, there are a number of products still in the testing phase, and no medications had been approved to cure vitiligo until July 2022. However, in a significant development, the U.S. Food and Drug Administration (FDA) approved the very first re-pigmentation therapy for non-segmental vitiligo in July 2022. This groundbreaking product is a cream called 1.5% ruxolitinib, marketed as Opzelura, and is specifically designed for patients aged 12 years and older. Incyte, a company based in the United States, is the one behind the development of this innovative treatment.
Additionally, information gathered from secondary sources indicates that there are currently around 52 ongoing trials for vitiligo treatment. Out of these, approximately 29 are in phase II trials, which means they are in the advanced stages of testing. The dedicated efforts by various players in the field to create new and improved products are expected to be a significant driver for market growth, especially when these products receive approval after successfully completing the necessary trials.
In essence, the progress of markets often hinges on the efforts put into research and clinical trials. These efforts lead to the development of better products that can make a positive impact on patient treatment. The journey from testing to approval is crucial, and in July 2022, a significant milestone was achieved with the FDA approving the first re-pigmentation therapy for vitiligo. This cream, Opzelura, is specifically designed for non-segmental vitiligo patients aged 12 years and older. The ongoing trials, especially those in phase II, hold promise for the future, and the approval of novel products resulting from these efforts is anticipated to drive substantial growth in the vitiligo treatment market in the coming years.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2023 | USD 1.593billion Billion |
Growth Rate | 6.20%(2023-2032) |
The Vitiligo Treatment Market size was valued at USD 1.47 billion in 2023. The Vitiligo Treatment Market industry is projected to grow from USD 1.55 billion in 2024 to USD 2.26 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.20% during the forecast period (2024 - 2032). The growing importance of aesthetic appeal and awareness, the increasing prevalence of vitligo, advancements in treatment options are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
In recent years, there has been a significant rise in beauty consciousness among consumers owing to the growing awareness among consumers about different aesthetic treatments, increasing per capita income and adoption of digital platforms. According to the International Society of Aesthetic Plastic Surgery (ISAPS), there was a 27.3% growth in worldwide total non-surgical procedures between 2015 and 2019. In addition, according to the American Society of Plastic Surgeons (ASPS), the number of minimally invasive aesthetic procedures witnessed about a 200% increase during 2000-2017. Moreover, about 15.9 million minimally invasive cosmetic procedures were performed in 2018, which was a 2% rise in comparison to 2017.
This is further boosted by the growing geriatric population globally and their willingness to retain their youthful appearances. Further, if patients have developed vitiligo and if not treated, the extent of its effects keep on increasing as the person ages. Hence, growing geriatric population is also a factor driving market growth. According to the ASPS, the population aged 40-54 years old made up 49% of the total cosmetic procedures in the US in 2018. This accounted for about 7.8 million total cosmetic procedures. Furthermore, the population aged 55 and above accounted for about 3.8 million minimally invasive procedures in 2018. Thus, the increasing geriatric population also drives the demand for minimally invasive cosmetic procedures.
The Vitiligo Treatment Market segmentation, based on Type, includes Segmental Vitiligo, and Non-Segmental Vitiligo. The Segmental Vitiligo segment is to hold the majority share in 2023 in the Vitiligo Treatment Market revenue. This is because of the rising healthcare expenditures and a growing number of specialized dermatology clinics are further propelling market growth. The demand for effective vitiligo treatments is expected to continue rising, as both patients and healthcare providers seek improved outcomes and quality of life.
The Vitiligo Treatment Market segmentation is based on a treatment that includes Therapy, Surgery and Medication. The Therapy segment has dominated the market in 2023 and Medication is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to advancements in medication. The increasing availability and effectiveness of treatments such as corticosteroids, calcineurin inhibitors, and novel biologics are enhancing patient outcomes and driving market expansion.
Figure 2: VITILIGO TREATMENT MARKET, BY APPLICATION, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Vitiligo Treatment Market segmentation is based on end-user that includes Hospitals, Ambulatory Clinics, and Others. The Hospitals segment has dominated the market in 2023 and the fastest-growing segment during the forecast period, 2024-2032. This is due to increasing role of hospitals. Hospitals are at the forefront of adopting advanced treatment options, such as phototherapy, skin grafting, and novel medications, enhancing patient care and treatment outcomes. The expansion of specialized dermatology departments and the availability of cutting-edge technologies in hospitals are driving market growth.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Vitiligo Treatment Market accounted for the largest market share in 2023. Due to advanced healthcare infrastructure and increasing awareness about skin disorders. The region's strong focus on research and development has led to the introduction of innovative treatments, including advanced phototherapy, biologics, and topical medications. High healthcare spending, coupled with the presence of key market players, is further propelling market expansion. Additionally, rising awareness campaigns and support groups for vitiligo patients are enhancing treatment uptake. With ongoing advancements and a robust healthcare system, the North American vitiligo treatment market is poised for continued growth in the coming years.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: VITILIGO TREATMENT MARKET BY REGION 2023 & 2032
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Vitiligo Treatment Market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating Vitiligo Treatment. Further, the German Vitiligo Treatment Market was attributed to holding the largest market share, and France Vitiligo Treatment Market is expected to fastest-growing market in the European region.
The Asia-Pacific Vitiligo Treatment market is expected to grow at the fastest rate from 2024 to 2032. This is due to improving healthcare infrastructure, coupled with rising healthcare expenditures, facilitating better access to advanced therapies. Additionally, the growing prevalence of vitiligo and the rising demand for cosmetic and dermatological treatments are significant drivers.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Vitiligo Treatment in the Middle East and Africa. MEA region has experienced Increasing global awareness and destigmatization of vitiligo are leading to higher diagnosis rates and a greater demand for effective treatments. Advances in medical technology and innovative treatment options, such as novel biologics and laser therapies, are enhancing patient outcomes and driving market expansion.
Vitiligo Treatment Key Market Players & Competitive Insights
The Vitiligo Treatment Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such Incyte (US), Bausch Health Companies Inc (Canada), Koninklijke Philips N.V. (Netherlands), Dr. Reddy's Laboratories Ltd (India), Strata Skin Sciences (US) dominate the Vitiligo Treatment Market due to Type differentiation, financial stability, strategic services, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global Vitiligo Treatment industry to benefit clients and expand the Vitiligo Treatment Market sector is to manufacture locally to reduce operating costs.
Key Companies in the Vitiligo Treatment Market include
Vitiligo Treatment Industry Developments
February 2022, STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced the commercial launch of its next generation excimer laser system, XTRAC Momentum™ 1.0, with the first installation in the United States.
In July 2022, Incyte's Opzelura™ (Ruxolitinib) Cream has been approved by the US FDA for the treatment of Vitiligo. Opzelura is the first and only FDA-approved repigmentation treatment for nonsegmental vitiligo.
In October 2021, The Uniza Group has launched a novel Vitiligo management solution. Vitellus is a novel combination of Greyverse, Melitane, GL 200, and EUK-134 that provides an advanced new age solution for Vitiligo management. Vitellus lotion is a three-in-one solution that promotes melamine growth, treats skin pigmentation, hair follicle pigmentation, and acts as a super antioxidant.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)